- Business

Aimmune shareholders accept $2 billion Nestle tender offer

ZURICH – Aimmune Therapeutics Inc AIMT.O shareholders have backed Nestle’s NESN.S $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer’s expiration date. “The minimum tender condition to the consummation of the offer set forth in the offer to purchase has been satisfied,” Nestle said.

About 123bioinformaticscom

Read All Posts By 123bioinformaticscom